TAK1 signaling is a potential therapeutic target for pathological angiogenesis
Authors:
- 10 May 2021
- journal article
- review article
- Published by Springer Nature in Angiogenesis
- Vol. 24 (3) , 453-470
Abstract
Angiogenesis plays a critical role in both physiological responses and disease pathogenesis. Excessive angiogenesis can promote neoplastic diseases and retinopathies, while inadequate angiogenesis can lead to aberrant perfusion and impaired wound healing. Transforming growth factor β activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, is a key modulator involved in a range of cellular functions including the immune responses, cell survival and death. TAK1 is activated in response to various stimuli such as proinflammatory cytokines, hypoxia, and oxidative stress. Emerging evidence has recently suggested that TAK1 is intimately involved in angiogenesis and mediates pathogenic processes related to angiogenesis. Several detailed mechanisms by which TAK1 regulates pathological angiogenesis have been clarified, and potential therapeutics targeting TAK1 have emerged. In this review, we summarize recent studies of TAK1 in angiogenesis and discuss the crosstalk between TAK1 and signaling pathways involved in pathological angiogenesis. We also discuss the approaches for selectively targeting TAK1 and highlight the rationales of therapeutic strategies based on TAK1 inhibition for the treatment of pathological angiogenesis.Keywords
Funding Information
- National Health and Medical Research Council (1185600)
- Excellent Young Scientists Fund (82000902)
This publication has 136 references indexed in Scilit:
- RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasisNature, 2012
- O‐GlcNAcylation of TAB1 modulates TAK1‐mediated cytokine releaseThe EMBO Journal, 2012
- Acute inhibition of TAK1 protects against neuronal death in cerebral ischemiaCell Death & Differentiation, 2011
- Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signalsClinical Immunology, 2010
- Targeting the hypoxia-inducible factor (HIF) pathway in cancerExpert Reviews in Molecular Medicine, 2009
- Direct activation of protein kinases by unanchored polyubiquitin chainsNature, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- The functions of animal microRNAsNature, 2004
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971